EMA Authorised: Lupkynis (voclosporin) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorized Lupkynis (voclosporin) for the treatment of lupus nephritis, marking EU approval for this therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• LUPKYNIS (voclosporin)

Snippet

Status: Authorised. Therapeutic area: Lupus Nephritis. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 17/11/2025